DR. DINA JOSEPH TEBCHERANY MD NPI 1578501664

NPI Details

DR. Dina Joseph Tebcherany, MD is a medical oncology internal medicine in Austin, TX with 33 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Dina Joseph Tebcherany, MD NPI is 1578501664. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

4101 JAMES CASEY ST
100
AUSTIN, TX
ZIP 78745-325
Phone: (512) 447-2202
Fax: (512) 447-3802

The NPI 1578501664 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Unclassified drugs (HCPCS:J3490)
• Uric acid level, blood (HCPCS:84550)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Red blood count, automated test (HCPCS:85045)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Folic acid level, serum (HCPCS:82746)
• Injection of drug or substance into vein (HCPCS:96374)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Vitamin d-3 level (HCPCS:82306)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)

The enumeration date for this NPI number is 6/2/2006 and was last updated on 2/10/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.